Genocea
Biosciences Inc. (Nasdaq: GNCA) reported disappointing results from a Phase
2a clinical trial of its pneumococcus vaccine GEN-004. The stock price plummeted $2.06 to close at $5.17.
Disappointing results for Genocea Biosciences
October 19, 2015 at 19:03 PM EDT
